CA1142083A - Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same - Google Patents

Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Info

Publication number
CA1142083A
CA1142083A CA000339541A CA339541A CA1142083A CA 1142083 A CA1142083 A CA 1142083A CA 000339541 A CA000339541 A CA 000339541A CA 339541 A CA339541 A CA 339541A CA 1142083 A CA1142083 A CA 1142083A
Authority
CA
Canada
Prior art keywords
membrane proteins
neisseria meningitidis
isolation
detergent
containing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000339541A
Other languages
English (en)
French (fr)
Inventor
Torsten B. Helting
Gerhard Guthohrlein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines GmbH
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Application granted granted Critical
Publication of CA1142083A publication Critical patent/CA1142083A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA000339541A 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same Expired CA1142083A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (de) 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
DEP2848965.8 1978-11-11

Publications (1)

Publication Number Publication Date
CA1142083A true CA1142083A (en) 1983-03-01

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000339541A Expired CA1142083A (en) 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Country Status (9)

Country Link
EP (1) EP0011243B1 (OSRAM)
JP (1) JPS5566519A (OSRAM)
AT (1) ATE857T1 (OSRAM)
AU (1) AU533386B2 (OSRAM)
CA (1) CA1142083A (OSRAM)
DE (2) DE2848965A1 (OSRAM)
DK (1) DK154841C (OSRAM)
ES (1) ES485715A1 (OSRAM)
IL (1) IL58673A (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317811A (en) 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
AU563317B2 (en) * 1982-12-02 1987-07-02 Rockefeller University, The Iga binding antibody
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1860191A3 (en) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
DK2255826T3 (en) 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7628995B2 (en) * 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US20090246224A1 (en) 2006-06-12 2009-10-01 Nathalie Devos Vaccine
NZ584683A (en) 2007-10-19 2012-05-25 Novartis Ag Neisseria meningitidis serogroup B vaccine formulations
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
BRPI0923006A2 (pt) 2008-12-17 2016-03-08 Novartis Ag vacinas meningococicas incluindo receptor de hemoglobina
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
EP2493499A1 (en) 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP2013521326A (ja) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
JP5848748B2 (ja) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc 感染症、炎症、呼吸器疾患などの処置に使用するtlr2アゴニストとしての化合物(システインベースのリポペプチド)および組成物
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
AR113011A1 (es) 2017-09-08 2020-01-15 Evelo Biosciences Inc Vesículas extracelulares bacterianas
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
AU2019376832B2 (en) 2018-11-06 2024-01-25 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
US10046048B2 (en) 2009-12-15 2018-08-14 Glaxosmithkline Biologicals S.A. Homogenous suspension of immunopotentiating compounds and uses thereof
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus

Also Published As

Publication number Publication date
DE2962526D1 (en) 1982-05-27
EP0011243B1 (de) 1982-04-14
IL58673A (en) 1983-02-23
ATE857T1 (de) 1982-04-15
DK154841C (da) 1989-06-05
AU533386B2 (en) 1983-11-24
DK475779A (da) 1980-05-12
AU5268279A (en) 1980-05-15
IL58673A0 (en) 1980-02-29
DE2848965A1 (de) 1980-05-22
EP0011243A1 (de) 1980-05-28
JPS5566519A (en) 1980-05-20
ES485715A1 (es) 1980-05-16
JPS6350332B2 (OSRAM) 1988-10-07
DK154841B (da) 1988-12-27

Similar Documents

Publication Publication Date Title
CA1142083A (en) Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same
US4271147A (en) Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
CN102356089B (zh) 脑膜炎球菌fHBP多肽
AU2010310985B2 (en) Modified meningococcal fHBP polypeptides
CN102596240B (zh) 包括脑膜炎球菌fHBP序列的杂交多肽
JP2911603B2 (ja) 新規な弱毒化シュードモナス・エルギノーザ株
CN102724988B (zh) 脑膜炎球菌fHBP多肽的表达
JPS61186400A (ja) 細菌由来中性多糖類と免疫原性タン白との安定な、共有結合された多糖―タンパク質結合体、該結合体の製造方法並びに該結合体を含む医薬組成物
JPH0819396A (ja) グラム−陰性球菌のリポオリゴ糖が除去された外膜蛋白質の製造および使用
EA034954B1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
CS244906B2 (en) Production method of antigen agent for limitation or prevention of tooth defects
EP0407037B1 (en) Process for removing bacterial endotoxin from gram-negative polysaccharides
CN106215183A (zh) 一种abc群脑膜炎球菌联合疫苗及其制备方法
EP0090660A2 (en) Neisseria gonorrhoeae vaccine
US6106842A (en) Extraction of cell-bound protein from bordetella
JPS5852227A (ja) 淋菌からの免疫原性複合体
RU2407792C1 (ru) СПОСОБ ПОЛУЧЕНИЯ IgAl-ПРОТЕАЗЫ ИЗ КУЛЬТУРЫ NEISSERIA MENINGITIDIS СЕРОГРУППЫ А И ИММУНОГЕННЫЙ ПРЕПАРАТ НА ЕЕ ОСНОВЕ
CN120754237B (zh) 含多价肺炎球菌多糖-蛋白结合物的免疫原性组合物及其制备方法和应用
KR810001317B1 (ko) 혼합백신의 제조방법
AU2015200160A1 (en) Modified meningococcal fHBP polypeptides
JPS59500615A (ja) ナイザ−淋菌ワクチン
JPS5946490B2 (ja) 抗アレルギ−剤及びその製法

Legal Events

Date Code Title Description
MKEX Expiry